What is the prevalence of Biliary Atresia?

Biliary atresia is a rare, life-threatening pediatric liver disease characterized by the progressive obstruction of the extrahepatic bile ducts, with an estimated global incidence ranging from 1 in 5,000 to 1 in 19,000 live births. While it is considered a rare disease, it remains the leading cause of pediatric liver transplantation worldwide, and accurate prevalence numbers are often difficult to capture due to the high mortality rate if left untreated in early infancy.

What is the estimated incidence and prevalence of Biliary Atresia?

The incidence of Biliary Atresia varies significantly by geography. In Western countries, the incidence is typically reported between 1 in 15,000 and 1 in 19,000 live births. However, the condition is notably more common in East Asian populations, such as Taiwan and Japan, where the incidence is reported as high as 1 in 5,000 to 1 in 9,000 live births. Because Biliary Atresia is a neonatal condition that requires urgent surgical intervention (the Kasai procedure) to prevent rapid progression to end-stage liver disease, "prevalence" is often measured in terms of surviving infants and children who have undergone liver transplantation or successfully managed the condition.

Are there demographic and geographic patterns in Biliary Atresia?

Research indicates distinct variations in how Biliary Atresia presents across different populations. Data suggests a slight female predominance in the "perinatal" (isolated) form of the disease, whereas the "embryonic" form, which is often associated with other congenital anomalies, shows no clear sex bias. Geographically, the higher incidence rates in Asian populations compared to North American or European populations remain a subject of intense medical research, pointing toward potential interplay between genetic predisposition and environmental triggers.

Why is accurate data for Biliary Atresia challenging to obtain?

Accurate epidemiological data for Biliary Atresia is complicated by several factors:

• Underdiagnosis: Early symptoms like jaundice can be confused with physiological jaundice of the newborn, delaying critical diagnostic testing.


• Reporting Gaps: Many registries track neonatal cases but struggle to follow long-term survivors into adulthood, making total prevalence figures difficult to aggregate.


• Diagnostic Variability: Variations in how hospitals code the disease—specifically distinguishing between syndromic and non-syndromic forms—can skew statistical reporting.

How does the DiseaseMaps community complement clinical data?

While formal clinical literature provides the foundational statistics for Biliary Atresia, real-world patient data provides essential context. Currently, 342 people with Biliary Atresia have joined the DiseaseMaps.org community. This network of patients and caregivers offers a unique, lived-experience perspective that helps identify common diagnostic delays and long-term quality-of-life challenges that are not always captured in traditional clinical incidence studies.

Next steps

• Consult a pediatric hepatologist or a center specializing in pediatric liver transplantation if you suspect symptoms of Biliary Atresia, such as persistent jaundice or acholic (pale) stools.


• Connect with the 342 members on DiseaseMaps.org to share experiences and find support regarding long-term care and liver health.


• Review resources from the American Liver Foundation or the Children's Liver Disease Foundation for the latest updates on management strategies.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician with any questions regarding a medical condition.

References

• Orphanet: Biliary Atresia (ORPHA:116)


• NIH Genetic and Rare Diseases Information Center (GARD): Biliary Atresia


• OMIM (Online Mendelian Inheritance in Man): Biliary Atresia (Entry #210500)


• Journal of Pediatric Gastroenterology and Nutrition: Global Perspectives on Biliary Atresia Epidemiology